Asuragen is a fully integrated molecular diagnostics company focused on oncology and companion diagnostics with special capabilities in the area of mRNA and miRNA. Based in Austin, Texas, we have strong R&D, regulatory, cGMP manufacturing and global commercial capabilities to support a broad range of molecular diagnostic products providing rapid identification of genetic abnormalities associated with oncology and genetic diseases.
Our diagnostic product portfolio consists of multiplex oncology assays, novel RT-qPCR leukemia products, innovative PCR assays for Fragile-X testing, RNA stabilization technologies, and industry-leading controls and standards engineered using our patented Armored RNA® technology. These products and technologies are supported by a portfolio of over 150 issued and pending patents relating to miRNAs, including exclusive rights to the “Ambion Patent Portfolio” in the field of human diagnostics.
The Asuragen Pharmacogenomic Services Division provides a comprehensive range of molecular services empowering its Pharma and Biotech clients to rapidly acquire a wide range of molecular data. Customers include 12 of the top 15 pharmaceutical companies and many other biotechnology companies. Asuragen’s rich legacy in RNA expertise serves as a focal point for a wide array of nucleic acid-based services, including analyte isolation/preparation from multiple sample types, genomic profiling, miRNA/mRNA expression profiling, biomarker discovery, assay design and validation, CLIA-based clinical testing, bioinformatics, and regulatory and project management services. Due to the breadth of its service offerings, Asuragen has become a leader in companion diagnostics by discovering and developing predictive and prognostic tests for our pharmaceutical and biotechnology partners. We “Enable Personalized Molecular Diagnostics.”